# Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

> **NCT06709521** · PHASE4 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 200 (estimated)

## Conditions studied

- Bacterial Infection

## Interventions

- **DRUG:** Iohexol

## Key facts

- **NCT ID:** NCT06709521
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709521, "Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06709521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*